Background: Optimal antibiotic exposure is a vital but challenging prerequisite for achieving clinical success in ICU patients.
Introduction
Appropriate dosing of antibiotic therapy is considered pivotal to decrease morbidity and improve outcome in critically ill patients with bacterial infections. [1] [2] [3] However, unpredictable physiological changes that cause altered and highly variable pharmacokinetics pose a significant challenge to effective antibiotic dosing in this population. 4 To further complicate issues, ICUs often harbour bacterial strains with reduced antibiotic susceptibility, increasing the risk of treatment failure due to subtherapeutic concentrations. [5] [6] [7] pharmacodynamic (PK/PD) targets in critically ill patients. [8] [9] [10] Data from a large prospective multicentre study suggested that empirical dosing of b-lactam antibiotics would result in unsatisfactory exposure in a large portion of ICU patients (19%/41% for ƒT .MIC ,50%/100%) infected with less susceptible pathogens, particularly if presenting high renal function and receiving intermittent instead of prolonged or continuous infusion. 10 Continuous infusion has been demonstrated to improve PK/PD target attainment in various further studies of time-dependent antibiotics, both for plasma and, importantly, peripheral target sites of infection. 9, 11, 12 Apart from improved drug exposure, previous studies have associated continuous infusion also with higher clinical cure rates in patients with severe sepsis 13, 14 and ventilatorassociated pneumonia 15 or better 30 day survival in patients with respiratory infections. 16 Furthermore, a recent meta-analysis suggested decreased hospital mortality in patients treated with continuous infusion of b-lactams, including meropenem. 17 Meropenem is an intravenous broad-spectrum carbapenem antibiotic frequently employed for the empirical treatment of severe nosocomial infections and is an appealing candidate for continuous infusion owing to its time-dependent antibacterial activity, short PK half-life and sufficient stability in infusion solutions at room temperature. [18] [19] [20] [21] Meropenem elimination is a major source of PK variability and predominantly occurs via renal excretion. 18, 22, 23 As measurements of creatinine clearance (CL CR ) are not routinely performed, surrogates of kidney function, e.g. based on serum creatinine (SCr), are frequently employed to guide dosing of renally cleared drugs such as meropenem. 24 However, there have been discussions of their accuracy in critically ill patients and evidence is lacking regarding which marker of renal function should be used to inform dose adjustments for meropenem. 25 Therefore, the present work aimed to develop and externally validate a population PK model for continuous-infusion meropenem considering routinely available markers of renal function in a large cohort of critically ill patients. We then sought to develop a nomogram translating renal function into daily doses of meropenem required to achieve specific target concentrations.
Patients and methods

Patients and ethics
We retrospectively analysed meropenem plasma concentrations collected during routine therapeutic drug monitoring (TDM) at the medical centre of Heidenheim, Germany (Kliniken Landkreis Heidenheim gGmbH) between 2009 and 2011. Adult critically ill patients, who received continuous infusion of meropenem and did not undergo renal replacement therapy, were analysed. The research was approved by the responsible institutional ethics committee (reference number 351/14; 12/2014).
Calculation of renal function
Renal function was estimated using the following SCr-based equations: Cockcroft-Gault creatinine clearance (CL CRCG ; 26 standard Cockcroft-Gault formula based on total body weight: CL CRCG_WT 
Drug administration
An initial loading dose of 500 mg, or in exceptional cases 1000 mg (as a 30 min intravenous infusion) was administered at the start of meropenem therapy (Meronem V R , AstraZeneca GmbH, Wedel, Germany). Subsequently, the maintenance dose was delivered as a continuous infusion (0.5-2 g reconstituted in 50 mL of 0.9% sodium chloride) via a syringe pump. Daily doses of meropenem were left to the discretion of the attending physician and were guided by the local dosing protocol based on CL CRCG , susceptibility of presumed/known causative pathogens and site of infection. In cases of severe infection with susceptible pathogens, steady-state concentrations (C SS ) of 8-16 mg/L were targeted (8 mg/L represents 4% the non-speciesrelated PK/PD breakpoint for susceptibility S 2 mg/L according to EUCAST as well as the susceptibility breakpoint for common pathogens such as Enterobacteriaceae or Pseudomonas aeruginosa). Over the course of therapy, doses were adjusted according to measured meropenem concentrations, identified pathogens and treatment response. Infusion syringes were changed every 6-24 h to comply with internally performed stability tests, revealing meropenem stability (!90% of initial amount, no turbidity) at 23 C over 8/18/24 h for 50/20/10 mg/mL solutions (0.9% sodium chloride; see Supplementary information and Figure S1 for further details as well as previous evidence on the stability of meropenem).
Blood sampling and analytical assays
Blood samples were drawn in the clinical routine setting at steady-state, at the earliest 6-24 h after the start of treatment. Meropenem concentrations were directly analysed following sampling. Total concentrations were measured using a validated HPLC method with UV detection based on a previously published assay. 30 For the analysis, 250 lL of patient sample was added to 50 lL of internal standard (0.2 mg/mL ertapenem) and 500 lL acetonitrile:methanol (LiChrosolv V R ), 1:1 v/v. Following centrifugation (5-10 min, 1800 g, 4 C), 200 lL of supernatant was mixed with 600 lL of water for injection and 50 lL of the solution was analysed by HPLC (Shimadzu Germany GmbH, Duisburg; the system comprised two LC-10AD vp pumps, an SIL-10AF vp autoinjector, an SCL-10 A vp system controller and an SPD-M10A vp diode array detector, wavelength 300 nm). Chromatographic separation was achieved using an RP-C18 column protected by a precolumn and gradient elution with a mobile phase composed of two buffers (A: water containing 0.5% formic acid; B: acetonitrile containing 0.25% formic acid and 4.75% water) at a flow rate of 1 mL/min over 15 min (retention time of meropenem and ertapenem: 8.5 and 10 min, respectively). The linear calibration range of meropenem was 1.00-50.0 mg/L. The relative standard deviation of interday and intraday precision was very low, 2.05%-2.76% and 0.30%-0.80%, respectively, and the relative error ( +1.5%) indicated high accuracy. SCr concentrations were determined by a modified Jaffe method using an Architect c8000 system (Abbott, Abbott Park, IL, USA).
Population PK modelling
Population PK modelling was performed using NONMEM V R 7.3 (Icon Development Solutions, Ellicott City, MD, USA), PsN 3.7.6 (Uppsala University, Uppsala, Sweden), the first-order conditional estimation with interaction method and the $PRED subroutine. Descriptive statistics and graphical analyses were conducted using R 3.2.2 (CRAN.R-project.org). Total meropenem clearance (L/h) was estimated from administered daily doses and corresponding C ss (mg/L) [CL " daily dose (mg)/(24 hÁC SS )].
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Renal function markers were implemented as covariates on clearance using linear and power functions (see Supplementary information for further details on the development of the PK model).
Following covariate analysis, further subgroup analyses were conducted. To assess the impact of multiple measurements per individual, model parameters were also estimated for a subset comprising only the first observation of each patient. A potential impact of unstable renal function on the parameter estimates was investigated by exclusion of all affected individuals and re-estimation of the model parameters. Unstable SCr was defined as .50% change from one measurement to the next, and from the first to the last measurement of individual observation periods.
Model adequacy was judged by statistical significance, i.e. decrease in the objective function value (DOFV ! 3.84, a " 0.05, df " 1 for nested models; see Supplementary information for further explanation), precision and plausibility of parameter estimates, standard goodness-of-fit plots (e.g. observed versus population and versus individual predicted concentrations, conditional weighted residuals versus predicted concentrations) and percentage of explanation of between-subject variability (BSV) associated with CL. A non-parametric bootstrap (n " 1000 replicate datasets) and prediction-corrected visual predictive checks (VPCs) were used to evaluate the precision of estimates and the predictive performance of the model.
External validation of the model
To check external validity, the model was applied to data independently gathered in 2014 in the same clinical setting, i.e. in the same ICUs, but in a different sample of adult critically ill patients, who required intensive care, received continuous infusion of meropenem and did not undergo renal replacement therapy. Measured meropenem concentrations of the external dataset were compared with those predicted by the developed model by means of goodness-of-fit plots, VPCs and calculation of normalized prediction distribution errors.
Probability of target attainment analyses and development of a nomogram
Based on the structural and BSV parameter estimates of the model, Monte Carlo simulations (n " 1000) were performed to assess meropenem exposure for varying doses (1000-8000 mg/day) and renal function values reflective of the observed population. In addition to the probability of attaining a target concentration of 8 mg/L (" 4 % EUCAST PK/PD susceptible/intermediate breakpoint for meropenem 31 ), the probability of target attainment (PTA) for a threshold of 32 mg/L (" 4 % EUCAST PK/PD resistant breakpoint 31 ) was determined, which-if exceeded-would put patients unnecessarily at higher risk of adverse drug reactions without apparent additional therapeutic benefit. 32, 33 For the nomogram, the 90th percentile of the BSV associated with CL and corresponding CL were calculated for varying renal function values and transformed into daily doses necessary to achieve target concentrations of 4, 8 and 16 mg/L.
Results
Patient characteristics
A total of 268 Caucasian critically ill patients who were admitted to an ICU were included in the analysis. Of these, 195 were considered for model development (433 of 604 meropenem concentrations); the most common indications for meropenem therapy (multiple options possible) were pneumonia (56.4%), sepsis (48.7%), peritonitis (23.6%), pancreatitis (4.10%), urinary tract infections (3.59%) and/or urosepsis (3.59%). Patients were mainly treated empirically, with a modal daily dose of 3000 mg/24 h (range 500-6000 mg/24 h), over a median duration of 6 days (range 1-33 days). Demographic and clinical data are described in Tables 1 and S1 (renal function markers).
Meropenem concentrations
A total of 433 meropenem concentrations (1-8/patient) were measured within up to 21 days during one course of therapy. Sixteen concentrations (3.70% of data) from six patients were determined during one (n patients " 5) or two (n patients " 1) further occasions, e.g. following separate hospital admissions, 18-104 days after the first treatment course. In .95% of all patients, the first sample was drawn after .12 h of therapy. The vast majority of individuals contributed to one or more further subsequent samples taken .24 h after the start of therapy.
Meropenem concentrations all exceeded the EUCAST clinical susceptibility breakpoint for Enterobacteriaceae of 2 mg/L 
Population pharmacokinetic modelling
All investigated markers of renal function significantly improved the model performance, most notably the standard CockcroftGault formula (sorted by statistical significance, i.e. DOFV 283-200: CL CRCG_WT #CL CRJEL #CL CRCG_WT_adj #CKD-EPI#MDRD#CL CRCG_mod # CL CRJEL_adj #CKD-EPI adj #MDRD adj , see Table S2 ). Formulas that considered the patients' actual BSA (mL/min) were superior to their variants adjusted to standard BSA (mL/min/1.73 m 2 ), both in terms of statistical significance (decrease in OFV) and explanation of BSV, with CL CRCG_WT leading to the largest (55.8%) and MDRD causing (Figure 1 ) and the VPC (Figure 2 ) both revealed an adequate description of the observed data by the model.
External model evaluation
A total of 171 meropenem measurements from 73 patients constituted the validation dataset. Daily doses (mode 3000 mg/24 h, range 500-6000 mg/24 h), meropenem concentrations (median C SS 13.7, range 3.0-47.6 mg/L) and patient characteristics of the external data largely resembled those of the model development dataset, with a slightly higher proportion of male patients (Table 1) . External evaluation confirmed the predictive performance of the model as demonstrated by goodnessof-fit plots, VPCs and normalized prediction distribution errors (Figure 3, Figure S2) , confirming that the model was suitable for dosing simulations.
Dosing nomogram and PTA analysis
The dosing nomogram that was established based on the linear CL-CL CRCG_WT relationship is depicted in Figure 4 , together with a general function to calculate the daily doses required to attain any desired target concentration. For example, to reach an efficacy threshold of 8 mg/L (solid line in the nomogram) in 90% of patients with CL CRCG_WT values of 20, 50, 80, 120 and 180 mL/min (x-axis), daily meropenem doses of 910, 1480, 2050, 2800 and 3940 mg (y-axis) would be required. PTA analysis ( Figure 5 ) indicated a low probability of adverse drug reactions (,0.5%) associated with these doses. 
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Discussion
The present study provided a nomogram for optimized continuousinfusion dosing of meropenem in a critically ill cohort based on a successfully validated population PK model. Of all routinely available SCr-based estimates of kidney function investigated, the Cockcroft-Gault equation was identified as best describing meropenem clearance and was therefore included in the nomogram. Our results confirm previous PK studies of meropenem, which almost uniformly demonstrate a considerable impact of renal function on exposure; this can be anticipated for hydrophilic antibiotics such as carbapenems. 16, [34] [35] [36] [37] [38] [39] [40] [41] Different markers of renal function have been related to meropenem clearance, including CL CR measured by urine collections 35, 38, 39, 42 or estimation equations such as CL CRCG . 16, 34, 36, 37, 43 However, to the best of our knowledge, no systematic comparison of various routinely available approximations of kidney function regarding their ability to predict meropenem clearance in ICU patients has yet been performed. Similar to our findings, the superiority of the Cockcroft-Gault formula, even compared with equations containing newer biomarkers for renal function, has been described also in ICU patients treated with other b-lactams, e.g. cefepime. 44 In our work, CL CRCG_WT accounted for more than half of the unexplained BSV associated with clearance, which is in agreement with a similar study. 37 The remaining variability might partly be due to diseaserelated factors potentially influencing meropenem clearance (e.g. disease severity) or to the non-renal contribution of meropenem elimination (e.g. metabolism to a microbiologically inactive compound or faecal elimination), which has been shown to exceed the renal pathway in individuals with renal impairment. 36, 45 Although significantly improving the meropenem model as well (DOFV 199 .58), the MDRD equation was the marker least predictive of meropenem clearance, presumably also owing to its development based on patients with chronic renal dysfunction only, while our population spanned a wide range of renal functions which would predominantly be driven by acute pathology.
In our analysis, the good performance of the standard Cockcroft-Gault formula CL CRCG_WT , which serves as the basis for dosing adaptations in the manufacturer's product label, 24 might be due to its weight component (total body weight), which is missing in all other investigated formulas. Predictability of meropenem clearance improved with anthropomorphic measures, i.e. formulas considering actual BSA (mL/min) performed better than their BSA-normalized versions (mL/min/1.73 m 2 ). Similar to our work, a previous study by Pai et al. 37 in obese patients provided nomograms based on CL CRCG rather than on BSA-normalized values of CL CRCG .
The present patient cohort displayed meropenem clearance values in the range of those published previously for critically ill patients receiving continuous infusion [7. 71 L/h (CL CRCG_WT " 80 mL/min) versus 8.85 L/h (CL CRCG_WT " 97 mL/min) in obese patients, 37 9.2 L/h (CL CRCG_WT " 80 mL/min) in surgical ICU patients, 7.7 L/h (CL CR 83.7 mL/min) in patients with pneumonia or sepsis 46 and 13.6 L/h (CL CR " 100 mL/min) in septic patients].
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The higher values of clearance reported in the literature might be partly due to better renal function or younger age in the studied population or determination based on a renal function marker other than CL CRCG_WT . 12, 38, 47, 48 As distinct markers of renal function differ in magnitude for the same population, deviating clearance values are obtained when estimated relative to the same reference kidney function, e.g. 80 mL/min (Table S2) .
Apart from (patho)physiological aspects, drug degradation might influence the apparent plasma clearance of a drug; however, this scenario was deemed unlikely in the present investigation as indicated by previous evidence of meropenem stability at 25 C as well as by internal stability tests at 23 C (see Supplementary information). 20, 21, 49 The established nomogram showed the antibiotic doses required to achieve plasma concentrations of 4/8/16 mg/L, thus 4 % MIC " 1/2/4 mg/L and .4 % MIC 0.5 mg/L. The selected magnitudes originated from findings associating b-lactam concentrations .4-6 % MIC with higher microbiological and clinical response or suppression of resistance. 47, 50, 51 If administered as continuous instead of intermittent infusions, standard daily doses of 3000 mg for patients with intact renal function (1000 mg q8h 24 ) would lead to meropenem C SS " 8 mg/L in !90% of patients with CL CRCG_WT 130 mL/min.
In patients with augmented renal function, higher than licensed daily doses would be necessary to maintain C SS !8 mg/L; given a target of C SS " 16 mg/L, higher than standard daily doses of 3000 mg were suggested by the nomogram even for a renal function of CL CRCG_WT .50 mL/min. According to the PTA analysis, higher than standard doses suggested by the nomogram for the target C SS " 8 mg/L (4000 mg, for CL CRCG_WT " 180 mL/min) did not lead to meropenem concentrations higher than C SS " 32 mg/L, putting patients unnecessarily at higher risk of adverse drug reactions, which is supported by a recent study that did not find a higher incidence of adverse events after administration of doses beyond those approved. 52 Regarding concentration-toxicity relationships of meropenem, Imani et al. 53 recently reported that meropenem threshold concentrations of C min " 64.2 mg/L and C min " 44.5 mg/L in plasma were associated with a 50% increased risk of a neurotoxic or nephrotoxic event during intermittent dosing, respectively. A previous study in septic ICU patients suggested that the risk of neurotoxicity increases with higher meropenem concentrations; more precisely, a C min /MIC 2mg/L ratio of !8 mg/L during intermittent administration was associated with worsening neurological status in $65% of the treated patients. 33 Thus, the upper threshold of C SS " 32 mg/L (representing 4% the EUCAST PK/PD resistant breakpoint) investigated in the present work represents a concentration for which higher values will not result in increased efficacy but for which toxicity is more likely and so seems a reasonable limit.
There are a few limitations to our study we would like to acknowledge. Our analysis was retrospective and based on data gathered during routine clinical practice. The investigated population was heterogeneous and details on patient outcomes and actual MIC values were lacking; thus, the present work focused on the PK of meropenem and on the attainment of clinical MIC breakpoints as targets rather than clinical outcomes. As meropenem Dosing nomogram for continuous-infusion meropenem in ICU patients JAC samples had exclusively been taken during continuous infusion and at steady-state, no volume of distribution could be estimated. However, total meropenem clearance and its relationship with renal function constitute the basis for steady-state dose calculations and were well captured by our model.
Next, no gold standard marker of kidney function (e.g. measured CL CR ) was available for the present analysis, which allowed conclusions regarding the relevance of different SCr-based renal function markers only for predicting meropenem clearance. Although some previous studies attributed limited accuracy to SCr-based surrogates of renal function in ICU patients, who did not represent the original target population of these formulas, or suggested measured CL CR to predict meropenem clearance in a small cohort of critically ill patients, 36 urine collection is usually not practicable in routine clinical practice and SCr commonly still represents the sole cost-effective marker of renal function readily available to optimize meropenem dosing. The impact of unstable SCr values on the CL-CL CRCG_WT relationship was found to be marginal in our study, which corresponds to previous findings. 37 Last, apart from successful external validation of the developed model, additional prospective validation of the nomogram should be performed in the future to further confirm its reliability and evaluate its efficiency in clinical practice. Caution is advised against extrapolation of the nomogram to any patients falling outside the characteristics of the studied cohort (e.g. with highly augmented renal function or undergoing dialysis). It should also be noted that the developed nomogram was based on steadystate data; prior to continuous infusion at therapy initiation, a loading dose is imperative to ensure rapid achievement of therapeutic exposure in critically ill patients.
The present work adds value in comparison with previously developed nomograms for continuous-infusion meropenem 37, 43 in that it was established based on a population PK model, which quantified the PK variability associated with meropenem elimination and distinguished between interpatient variability and residual, e.g. drug assay-related, variability; only the relevant interpatient variability was considered in the nomogram. Furthermore, the nomogram was built on the data of a large patient cohort spanning broad ranges of renal function and weight. Hence, owing to consideration of variability in the developed nomogram, the proposed daily doses, which were associated with 90% of the patients attaining the target concentrations, were naturally slightly higher compared with those by Pea et al. 43 Overall, nomograms should not preclude the use of TDM coupled with Bayesian forecasting, considering both clinical covariates and measured antibiotic serum concentrations for individual dose adjustments. 54, 55 However, according to a recent study, TDM for carbapenems has not been implemented in .90% of ICUs 56 and in these settings, nomograms could provide hints about patients at risk of not attaining effective antibiotic concentrations during continuous infusion of standard doses, e.g. challenging patients with unimpaired renal clearance or infected with less susceptible pathogens.
In conclusion, we successfully developed and externally validated a population PK model for continuous-infusion meropenem based on a large cohort of critically ill patients exhibiting a wide range of renal function. We identified standard Cockcroft-Gault CL CR to be the most adequate predictor of meropenem clearance and generated a nomogram translating renal function into the daily maintenance doses needed to reliably attain target concentrations.
